Whilst we are all keen to get in on the potential cure experiment front for covid-19, I ask the question. Is there a risk of rushing in trying to provide a treatment to a patient perhaps unfortunately on death's door and a unsuccessful outcome taints our otherwise impressive product? Not because of the treatment, but the circumstances related to the patient health prior. Will that be the thing that gets remember more than the effort? Or of course on the other hand a successful outcome would make world headlines!
Risks worth considering?
Cynata has manufacturing solution for new covd treatments, page-38
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.020(8.16%) |
Mkt cap ! $40.68M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 22.5¢ | $32.92K | 143.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 21235 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 17528 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |